Meet The Professors

A case-based discussion on the management of colorectal cancer in the adjuvant and metastatic settings



EDITOR
Neil Love, MD

FACULTY

Steven A Curley, MD Charles S Fuchs, MD, MPH Daniel G Haller, MD Neal J Meropol, MD



from the publishers of





Meet The Professors: A case-based discussion on the management of colorectal cancer in the adjuvant and metastatic settings

STATEMENT OF NEED/TARGET AUDIENCE

Colorectal cancer is among the most common cancers in the United States, and the arena of colorectal cancer treatment continues to evolve. Published results from ongoing clinical trials lead to the emergence of new therapeutic agents and regimens and changes in indications, doses and schedules for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. In order to incorporate research advances into developing treatment strategies for patients, the CME program *Meet The Professors* utilizes case-based discussions between community oncologists and research leaders.

LEARNING OBJECTIVES

- Critically evaluate the clinical implications of emerging clinical trial data in colorectal
 cancer treatment and incorporate these data into management strategies in the neoadjuvant, adjuvant and metastatic settings.
- Counsel appropriately selected patients about the availability of ongoing clinical trials.
- Evaluate the emerging data on various adjuvant chemotherapy approaches, including the use of oxaliplatin-containing regimens and the use of capecitabine or intravenous 5-FU, and explain the absolute risks and benefits of these regimens to patients.
- Integrate emerging data on biologic therapies into the management of colorectal cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs or tapes, review the CME information and complete the Evaluation Form located in the back of this book or on our website, MeetTheProfessors.com.

Guide to Audio Program

Audio Tape 1: Side A — case from Dr Glynn, case from Dr Weinstein, case from Dr Hussein, case from Dr Harwin; Side B — case from Dr Harwin (continued), case from Dr Grabelsky, case from Dr Gastesi

Audio Tape 2: Side A — case from Dr Hart, case from Dr Weinstein; Side B — case from Dr Kurian, case from Dr Vacirca, case from Dr Reeves, case from Dr Towell

Compact Disc 1: Tracks 1-4 — case from Dr Glynn; Tracks 5-7 — case from Dr Weinstein; Tracks 8-12 — case from Dr Hussein; Tracks 13-18 — case from Dr Harwin; Tracks 19-23 — case from Dr Grabelsky

Compact Disc 2: Tracks 1-5 — case from Dr Grabelsky (continued); Tracks 6-11 — case from Dr Gastesi; Tracks 12-18 — case from Dr Hart; Tracks 19-24 — case from Dr Weinstein

Compact Disc 3: Tracks 1-4 — case from Dr Weinstein (continued); Tracks 5-6 — case from Dr Kurian; Tracks 7-10 — case from Dr Vacirca; Tracks 11-15 — case from Dr Reeves; Tracks 16-19 — case from Dr Towell

Faculty Affiliations



Steven A Curley, MD
Professor of Surgical
Oncology
Chief, Gastrointestinal
Tumor Surgery
The University of Texas
MD Anderson Cancer Center
Houston. Texas



Daniel G Haller, MD Professor of Medicine Abramson Cancer Center at the University of Pennsylvania Philadelphia, Pennsylvania



Charles S Fuchs, MD, MPH Associate Professor of Medicine Dana-Farber Cancer Institute Harvard University Boston, Massachusetts



Neal J Meropol, MD
Director, Gastrointestinal
Cancer Program
Director, Gastrointestinal
Tumor Risk Assessment
Program
Divisions of Medical
Science and Population
Science
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Medical Oncologist Community Panel

Roman A Gastesi, MD Ft Lauderdale, Florida Philip Glynn, MD Springfield, Massachusetts Stephen A Grabelsky, MD Boca Raton, Florida Lowell L Hart, MD, FACP Fort Myers, Florida William N Harwin, MD
Fort Myers, Florida
Atif M Hussein, MD
Hollywood, Florida
Sobha Kurian, MD
Morgantown, West Virginia
William G Reeves, MD
Youngstown, Ohio

Brenda L Towell, MD Austin, Texas Jeffrey L Vacirca, MD East Setauket, New York Paul L Weinstein, MD Stamford, Connecticut

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-theart education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Chris Thomson, MD, MS, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech Inc/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Curley — Consulting Fees: Genentech Inc, Sanofi-Aventis. Dr Fuchs — Honoraria: Genentech Inc, Pfizer Inc, Sanofi-Aventis. Dr Haller — Consulting Fees: Genentech Inc, Roche Laboratories Inc, Sanofi-Aventis; Contracted Research: Bristol-Myers Squibb Company, Roche Laboratories Inc, Sanofi-Aventis. Dr Meropol — Consulting Fees: Amgen Inc, Genentech Inc, Pfizer Inc.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Case Studies

- Case 1: A 71-year-old woman with a large primary lesion located in the cecum, innumerable hepatic lesions, an LDH of 2,406 and a CEA of 474, which rose to 924 following her first cycle of FOLFOX (from the practice of Dr Philip Glynn)
- Case 2: A 74-year-old man with a poorly differentiated adenocarcinoma in the ascending colon and four out of five positive lymph nodes with a history of diabetes and significant coronary artery disease (from the practice of Dr Paul L Weinstein)
- Case 3: A 43-year-old man with a four-centimeter, poorly differentiated rectal adenocarcinoma with lymphatic invasion and multiple enlarged lymph nodes on endorectal ultrasound (from the practice of Dr Atif M Hussein)
- Case 4: A 77-year-old woman with solitary liver metastases three and a half years after resection of the colon followed by six months of adjuvant Roswell Park 5-FU/leucovorin for a bulky, node-negative tumor fixed to the pelvic sidewall (from the practice of Dr William N Harwin)
- Case 5: An 82-year-old man with a moderately differentiated adenocarcinoma in the right colon at the hepatic flexure with one out of 12 positive lymph nodes, preexisting hypertension, hyperlipidemia and minimal lower-extremity peripheral neuropathy related to spinal stenosis (from the practice of Dr Stephen A Grabelsky)
- Case 6: A 54-year-old man with a five-centimeter adenocarcinoma of the colon fixed to the pelvic wall, invading the bladder and with peritoneal implants (*from the practice of Dr Roman A Gastesi*)
- Case 7: A 57-year-old woman with a 2.4-centimeter, moderately differentiated colorectal tumor with no lymphovascular invasion, zero out of three positive nodes and a history of polycystic kidney and liver disease (from the practice of Dr Lowell L Hart)
- Case 8: A 59-year-old woman with a history of a moderately differentiated, cecal adenocarcinoma diagnosed at age 53 with four out of 17 positive nodes who develops liver metastases (from the practice of Dr Paul L Weinstein)
- Case 9: A 60-year-old woman with an adenocarcinoma in the cecum, 14 out of 20 positive nodes and liver metastases (from the practice of Dr Sobha Kurian)
- Case 10: An 80-year-old woman with an adenocarcinoma of the cecum and three discrete liver lesions, the largest being five by three and a half centimeters (from the practice of Dr Jeffrey L Vacirca)
- Case 11: A 50-year-old woman with Stage II colorectal cancer and zero out of 25 positive nodes (from the practice of Dr William G Reeves)
- Case 12: A 67-year-old man with T3/N0 rectal cancer and synchronous hepatic metastases, with six lesions seen on MRI and eight detected on PET scan (from the practice of Dr Brenda L Towell)

Evaluation Form: Meet The Professors Colorectal Cancer, Issue 1, 2006

Research To Practice respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please complete this evaluation form. A certificate of completion will be issued upon receipt of your completed evaluation form.

m.t													
Please answer t	he followi 4 =	ng questio 3 =	ns by	cir	cling the	appropri = 1		rat	ting	_	/A =		
Outstanding	Good	Satisfac	tory		Fair	Poo				app	lica ue o	ble	
GLOBAL LEARN													
To what extent do								ear	nin	g o	bje	ctiv	es?
 Critically evaluate colorectal cancer t strategies in the n 	reatment an	d incorporate	e thes	e dat	a into man	agement			5	5 4	3 2	2 1	N/A
• Counsel appropriat of ongoing clinical									5	5 4	3 2	2 1	N/A
 Evaluate the emergincluding the use of capecitabine or into benefits of these remarks. 	of oxaliplatir travenous 5-	n-containing FU, and expl	regim ain th	ens a	and the use solute risks	of and			5	5 4	3 2	2 1	N/A
Integrate emerging of colorectal cancer									5	5 4	3 2	2 1	N/A
EFFECTIVENESS	OF THE	INDIVIDU	JAL	FAC	ULTY M	EMBERS	5						
Faculty		Knowledge	e of su	ıbjec	t matter	Effec	tive	nes	s as	an	edu	cato	r
Steven A Curley, MD	1		e of s u	ı bjec 2	t matter	Effec	tive	1es 4	s as	2 2	edu 1	cato	r
-		5		•		Effec						cato	or
Steven A Curley, MD		5	4 3	2	1	Effec	5	4	3	2	1	cato	or
Steven A Curley, MD Charles S Fuchs, MD		5 · · · · · · · · · · · · · · · · · · ·	4 3	2	1	Effec	5	4	3	2	1	cato	or
Steven A Curley, MD Charles S Fuchs, MD Daniel G Haller, MD Neal J Meropol, MD	, MPH	5 · · · · · · · · · · · · · · · · · · ·	4 3 4 3 4 3 4 3	2 2 2	1 1 1	Effec	5 5 5	4 4 4	3 3	2 2 2	1 1 1	cato	or
Steven A Curley, MD Charles S Fuchs, MD Daniel G Haller, MD Neal J Meropol, MD	, MPH	5 · · · · · · · · · · · · · · · · · · ·	4 3 4 3 4 3 4 3	2 2 2 2 TIV	1 1 1 1		5 5 5 5	4 4 4	3 3 3	2 2 2	1 1 1	cato	
Steven A Curley, MD Charles S Fuchs, MD Daniel G Haller, MD Neal J Meropol, MD	TIVENES	5 5 5 5 5 5 5 5 5 F THE rall purpose	4 3 4 3 4 3 4 3 E AC	2 2 2 2 TIV	1 1 1 1 1 TY of activity		5 5 5	4 4 4	3 3 3	2 2 2	1 1 1		1
Steven A Curley, MD Charles S Fuchs, MD Daniel G Haller, MD Neal J Meropol, MD OVERALL EFFEC Objectives were rela	, MPH CTIVENES ated to ove	5 5 5 5 5 5 5 5 5 S OF THE	4 3 4 3 4 3 E AC	2 2 2 TIV	1 1 1 1 ITY of activity		5 5 5	4 4 4 4	3 3 3 3	2 2 2 2	1 1 1 1	2	1 1
Steven A Curley, MD Charles S Fuchs, MD Daniel G Haller, MD Neal J Meropol, MD OVERALL EFFEC Objectives were rela Related to my pract	, MPH CTIVENES ated to ove tice needs . I practice .	5 5 5 5 5 5 S OF THE rall purpose	4 3 4 3 4 3 4 3 E AC	2 2 2 2 TIV	1 1 1 1 ITY of activity		5 5 5 	4 4 4 4	3 3 3 3 5	2 2 2 2 4 4	1 1 1 1 3 3	2 2	1 1 1
Steven A Curley, MD Charles S Fuchs, MD Daniel G Haller, MD Neal J Meropol, MD OVERALL EFFEC Objectives were rela Related to my pract Will influence how	, MPH CTIVENES ated to ove cice needs . I practice . ve patient c	5 5 5 5 5 S OF THE rall purpose	4 3 4 3 4 3 E AC	2 2 2 2 TIV	1 1 1 1 ITY of activity		5 5 5	4 4 4 4	3 3 3 3	2 2 2 2 4 4 4	1 1 1 1 3 3 3	2 2 2 2	1 1 1 1
Steven A Curley, MD Charles S Fuchs, MD Daniel G Haller, MD Neal J Meropol, MD OVERALL EFFEC Objectives were rela Related to my pract Will influence how i	, MPH CTIVENES ated to ove tice needs . I practice . we patient cullectual cur	5 5 5 S OF THE rall purpose	4 3 4 3 4 3 E A C	2 2 2 2 2 TIV ((s) (1 1 1 1 ITY of activity		5 5 5	4 4 4 4	3 3 3 3 3 5 5 5 5	2 2 2 2 4 4 4 4 4	1 1 1 1 3 3 3 3	2 2 2 2 2	1 1 1 1 1
Steven A Curley, MD Charles S Fuchs, MD Daniel G Haller, MD Neal J Meropol, MD OVERALL EFFEC Objectives were rela Related to my pract Will influence how : Will help me improv Stimulated my intel Overall quality of m Overall, the activity	TIVENES ated to ove cice needs. I practice ove patient cullectual curvaterial	5 5 5 S OF THE rall purpose are	4 3 4 3 4 3 E AC	2 2 2 2 TIV ((s) (· · · · · · · · · · · · · · · · · · ·	1 1 1 1 ITY of activity		5 5 5	4 4 4 4	3 3 3 3 3 5 5 5 5 5 5 5 5	2 2 2 2 4 4 4 4 4 4	1 1 1 3 3 3 3 3	2 2 2 2 2 2	1 1 1 1 1 1
Steven A Curley, MD Charles S Fuchs, MD Daniel G Haller, MD Neal J Meropol, MD OVERALL EFFEC Objectives were rela Related to my pract Will influence how i Will help me improv Stimulated my intel Overall quality of m	TIVENES ated to ove cice needs. I practice ove patient cullectual curvaterial	5 5 5 S OF THE rall purpose are	4 3 4 3 4 3 E AC	2 2 2 2 TIV ((s) (· · · · · · · · · · · · · · · · · · ·	1 1 1 1 ITY of activity		5 5 5	4 4 4 4	3 3 3 3 3 5 5 5 5 5 5 5 5	2 2 2 2 4 4 4 4 4 4 4	1 1 1 3 3 3 3 3 3	2 2 2 2 2 2 2	1 1 1 1 1 1 1

Evaluation Form: Meet The Professors Colorectal Cancer, Issue 1, 2006
REQUEST FOR CREDIT — Please Print Clearly
Name: Specialty:
Degree: MD DO PharmD NP BS RN PA Other
Medical License/ME Number: Last 4 digits of SSN# (required):
Street Address:
Box/Suite: City, State, Zip:
Phone Number: Fax Number:
Email:
Research To Practice designates this educational activity for a maximum of 3.5 AMA PR Category 1 Credit(s)". Physicians should only claim credit commensurate with the extended their participation in the activity. I certify my actual time spent to complete this educational activity to be hour(s).
Signature:
Will the information presented cause you to make any changes in your practice? ☐ Yes ☐ No
If yes, please describe any change(s) you plan to make in your practice as a result of this activity.
What other topics would you like to see addressed in future educational programs?
What other faculty would you like to hear interviewed in future educational program
Additional comments about this activity:
FOLLOW-UP
As part of our ongoing, continuous quality-improvement effort, we conduct postactivit follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:
☐ Yes, I am willing to participate in a follow-up survey.☐ No, I am not willing to participate in a follow-up survey.
To obtain a certificate of completion and receive credit for this activity, please fill out the Evaluation Form and mail or fax to: Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131, FAX 305-377-9998. You may also complete the Evaluation online at MeetTheProfessors.com/CME.

Meet The Professors

Editor/CME Director Neil Love, MD

Managing Editor Kathryn Ault Ziel, PhD
Scientific Director Richard Kaderman. PhD

Writers Lilliam Sklaver Poltorack, PharmD

Douglas Paley

Continuing Education

Administrator for Nursing Sally Bogert, RNC, WHCNP

Content Validation Margaret Peng

Ginelle Suarez Erin Wall Aura Herrmann

Director, Creative and Copy Editing

Creative Manager Fernando Rendina

Graphic Designers Jason Cunnius

Tamara Dabney Shantia Daniel Elisa Stambouli

Senior Production Editor

Alexis Uneca

Managing Production Coordinator Tere Sosa

Dave Amber

Mary DiNunzio Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin

Carol Peschke Susan Petrone

Production Manager

Copy Editors

Patricia Kappes Frank Cesarano

Audio Production Technical Services

Arly Ledezma John Ribeiro

Contact Information

Web Master

Neil Love, MD

Research To Practice One Biscayne Tower

2 South Biscayne Boulevard, Suite 3600

Miami, FL 33131 Fax: (305) 377-9998

Email: NLove@ResearchToPractice.net

For CME Information

Email: CME@ResearchToPractice.net

Copyright @ 2006 Research To Practice. All rights reserved.

This program is supported by education grants from Roche Laboratories Inc and Sanofi-Aventis.

The audio tapes, compact discs, internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Copyright © 2006 Research To Practice.
This program is supported by education grants from
Roche Laboratories Inc and Sanofi-Aventis.



Sponsored by Research To Practice.

Last review date: November 2006 Release date: November 2006 Expiration date: November 2007 Estimated time to complete: 3.5 hours